Silence Therapeutics plc Share Price London S.E.
Stocks
GB0008433350
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| Market Cap | 59Cr 80Cr 69Cr 64Cr 110.69Cr 7.62TCr 111.78Cr 757.39Cr 294.85Cr 3.85TCr 300.27Cr 293.73Cr 13TCr | P/E 2026 * |
-19.7x | P/E 2027 * | -16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 45Cr 62Cr 53Cr 50Cr 86Cr 5.89TCr 86Cr 585.52Cr 227.94Cr 2.97TCr 232.13Cr 227.07Cr 9.85TCr | EV / Sales 2026 * |
1,396x | EV / Sales 2027 * | 550x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 01/12/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 01/02/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 21/06/2018 |
Iain Ross
CHM | Chairman | 72 | 01/01/2004 |
Tim McInerney
BRD | Director/Board Member | 65 | 05/05/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.02% | +4.84% | +4.80% | +24.36% | 5.12TCr | |
| -0.09% | -2.14% | +492.60% | +537.84% | 4.53TCr | |
| -0.32% | +8.08% | +37.97% | +18.45% | 4.28TCr | |
| +1.18% | +1.96% | +21.95% | +89.69% | 4.23TCr | |
| -2.27% | -5.67% | +14.55% | +50.34% | 3.22TCr | |
| -0.96% | +4.03% | +31.55% | +136.34% | 1.73TCr | |
| +0.41% | +1.66% | - | - | 1.65TCr | |
| +1.12% | +5.83% | +8.37% | +32.33% | 1.48TCr | |
| -0.31% | +6.61% | +81.37% | +48.53% | 1.43TCr | |
| Average | +0.00% | +3.06% | +86.64% | +117.24% | 3.08TCr | |
| Weighted average by Cap. | +0.10% | +2.89% | +105.43% | +135.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 4L 4L 4L 6L 4.22Cr 6L 41.93L 16.32L 2.13Cr 16.63L 16.26L 7.05Cr | 8L 10.23L 9L 8L 14.16L 9.76Cr 14.3L 96.92L 37.73L 4.92Cr 38.42L 37.59L 16Cr |
| Net income | -4.14Cr -5.65Cr -4.84Cr -4.54Cr -7.82Cr -538.77Cr -7.9Cr -54Cr -21Cr -271.82Cr -21Cr -21Cr -900.19Cr | -6.63Cr -9.04Cr -7.74Cr -7.26Cr -13Cr -861.56Cr -13Cr -86Cr -33Cr -434.68Cr -34Cr -33Cr -1.44TCr |
| Net Debt | -13Cr -18Cr -16Cr -15Cr -25Cr -1.73TCr -25Cr -171.87Cr -67Cr -872.83Cr -68Cr -67Cr -2.89TCr | -17Cr -24Cr -20Cr -19Cr -33Cr -2.26TCr -33Cr -224.74Cr -87Cr -1.14TCr -89Cr -87Cr -3.78TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
